AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

by Barry101 | Mar 25, 2024 | Press Release

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis...

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

by Barry101 | Mar 22, 2024 | Press Release

OCALA, Fla., March 22, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels,...

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

by Barry101 | Mar 20, 2024 | Press Release

OCALA, Fla., March 20, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels,...

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

by Barry101 | Mar 15, 2024 | Press Release

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ETOCALA, Fla., March 15, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it...

AIM ImmunoTech Announces Launch of CEO Corner Platform

by Barry101 | Mar 7, 2024 | Press Release

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future videos Access the AIM CEO Corner Here! OCALA, Fla., March 07, 2024...